1. Evidence
The Osprey registry should hold significant data. Now it's closed good time to write it up.
The TRIPP study is 75% recruited so the first RCT evidence of Oncosil
The PANCOSIL study also almost fully recruited (not RCT)
GBA study will be RCT
2.Availability and price
Readily available and the start of Australian manufacturing will reduce cost and price.
3. Respect and adoption
Will be reflected in investigator led trials and number of hospitals doing their first implant
4.Hospital networks
You would think that all hospitals currently in the TRIPP study and then the future GBA study will have integrated it into their systems
5.Driven and experienced team
I think we have that.
6.Leader/CEO/Board
I think Nigel is great, but the institutions are resisting, the last CR was bad, and there are obviously some games being played by shareholders that the Board can't seem to control.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.02 |
Change
0.020(2.00%) |
Mkt cap ! $14.50M | |||
| Open | High | Low | Value | Volume |
| $1.00 | $1.04 | 99.5¢ | $44.55K | 44.45K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 192 | $1.03 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.04 | 6234 | 1 |
View Market Depth
| Last trade - 15.48pm 25/06/2025 (20 minute delay) ? |
| OSL (ASX) Chart |